Routine Short-Term Ureteral Stent in Living Donor Renal Transplantation: Introduction of a Simple Stent Removal Technique Without Using Anesthesia and Cystoscope

2011 ◽  
Vol 43 (10) ◽  
pp. 3747-3750 ◽  
Author(s):  
J. Dong ◽  
J. Lu ◽  
Q. Zu ◽  
S. Yang ◽  
S. Sun ◽  
...  
Keyword(s):  
Renal Transplantation ◽  
Living Donor ◽  
Ureteral Stent ◽  
Short Term ◽  
Stent Removal ◽  
Removal Technique

scholarly journals Comparison of a magnetic retrieval device vs. flexible cystoscopy for removal of ureteral stents in renal transplant patients: A randomized controlled trial

2020 ◽  
Vol 15 (2) ◽  
Author(s):  
Anil Kapoor ◽  
Jason Akerman ◽  
Emily Wong ◽  
Gaurav Vasisth ◽  
Fadil Hassan ◽  
...  
Keyword(s):  
Renal Transplantation ◽  
Renal Transplant ◽  
Controlled Trial ◽  
Ureteral Stent ◽  
Flexible Cystoscopy ◽  
Stent Removal ◽  
Transplant Patients ◽  
Renal Transplant Patients ◽  
Tract Infections ◽  
Retrieval Device

Introduction: Placement of a ureteral stent at the time of renal transplantation can reduce complications when compared to non-stented anastomoses. Removal by flexible cystoscopy can be associated with discomfort, risk for infection, and high costs. New magnetic stents offer a means of bypassing cystoscopy by use of a magnetic retrieval device. Our objective was to compare clinical and cost-related outcomes of conventional and magnetic stents in patients undergoing deceased donor renal transplantation. Methods: Patients were randomized to receive either a conventional or a Black-Star® magnetic stent. Clinical, procedural, and cost outcomes were assessed, and the Ureteral Stent Symptom Questionnaire (USSQ) was administered with the stent in situ and after stent removal. All variables were compared between groups. Results: Forty-one patients were randomized to conventional (n=19) or Black-Star (n=22) stent. The total time for stent removal under cystoscopy was significantly longer compared to Black-Star removal (6.67±2.47 and 4.80±2.21 minutes, respectively; p=0.019). No differences were found in the USSQ domains between groups. Rates of urinary tract infections and surgical complications between groups were similar. Stent removal was well-tolerated in both groups. Black-Star stent use resulted in a cost savings of $304.02 Canadian dollars (CAD) per case. Conclusions: USSQ scores suggest that stent removal with the Black-Star magnetic stent is as equally well-tolerated as flexible cystoscopy by renal transplant patients. Black-Star stent removal was significantly faster than conventional stents. No differences in discomfort, infection rate, or complication rate were found. Use of the Black-Star stent resulted in an estimated annual savings of $27 360 CAD at our centre.

scholarly journals Innovation and new technology in ureteral stents

2021 ◽  
Vol 42 (2) ◽  
pp. 160-168
Author(s):  
Tongtra Watcharawittayakul ◽  
◽  
Manint Usawachintachit ◽  
Keyword(s):  
Clinical Trials ◽  
New Technology ◽  
Material Design ◽  
Ureteral Stent ◽  
Biodegradable Materials ◽  
Stent Insertion ◽  
Ureteral Stents ◽  
Stent Removal ◽  
Silicone Polymers ◽  
Removal Technique

Ureteral stent insertion is a procedure performed extensively by all urologists. Nevertheless, stent-related symptoms and stent encrustation are still common complications pushing the innovation and development of novel ureteral stents. Developments are focussing on three significant aspects: material, design, and removal technique. Various materials including silicone, polymers, and metals are frequently utilized, with or without an additional coating. The use of biodegradable materials is looking promising but these is a lack of proven clinical trials in association with this in humans. The new designs focus on the reduction of stent-related symptoms through the modification of the bladder end. The new stent removal techniques with extraction strings or novel magnetic end may exclude subsequent cystoscopic procedures. Finally, utilization of a ureteral stent tracker application helps in reminding both physicians and patients to remove the stent at the appropriate time.

scholarly journals SP656LONG−TERM OUTCOME OF RANDOMIZED TRIAL COMPARING CYCLOSPORINE AND TACROLIMUS THERAPY WITH STEROID WITHDRWAL IN LIVING−DONOR RENAL TRANSPLANTATION: 10−YEAR FOLLOW UP

2016 ◽  
Vol 31 (suppl_1) ◽  
pp. i313-i314
Author(s):  
Jin Hae Kim ◽  
Do Hee Kim ◽  
Jee Eun Park ◽  
Hye Ryoun Jang ◽  
Jung Eun Lee ◽  
...  
Keyword(s):  
Renal Transplantation ◽  
Randomized Trial ◽  
Living Donor ◽  
Term Outcome ◽  
Tacrolimus Therapy

scholarly journals Urolithiasis in renal transplantation: Diagnosis and management

2014 ◽  
Vol 86 (4) ◽  
pp. 257 ◽  
Author(s):  
Elisa Cicerello ◽  
Franco Merlo ◽  
Mario Mangano ◽  
Giandavide Cova ◽  
Luigi Maccatrozzo
Keyword(s):  
Renal Transplantation ◽  
Shock Wave Lithotripsy ◽  
Renal Allograft ◽  
Stone Formation ◽  
Urinary Calculi ◽  
The Other ◽  
Ureteral Stent ◽  
Nephrostomy Tube ◽  
Staghorn Calculus ◽  
Multimodal Management

Obiectives: To report our experience of diagnosis and multimodal management of urolithiasis in renal transplantation. Patients and Methods: From January 1995 to December 2012, 953 patients underwent renal transplantation in the Kidney Transplant Unit of Treviso General Hospital. Ten (10%) of them developed urinary calculi and were referred at our institution. Their mode of presentation, investigation and treatment were recorded. Results: Seven had renal and 3 ureteral calculi. Urolithiasis was incidentally discovered on routine ultrasound in 6 patients, 1 presented with oliguria, 1 with anuria and acute renal failure and in 2 urolithiasis was found at removal of the ureteral stent. Nephrostomy tube was placed in 5 patients. Hypercalcemia with hyperparathyroidism (HPT) was present in 5 patients and hyperuricemia in 3. Two patients were primary treated by shock wave lithotripsy (SWL) and one of them was stone-free after two sessions. Two patients, one with multiple pielocaliceal calculi and the other with staghorn calculus in the lower calyx, were treated with percutaneous nephrolitothotomy (PCNL). Three patients were treated by ureteroscopy (URS) and in one of them two treatments were carried out. One patient had calculus impacted in the uretero-vesical anastomosis and surgical ureterolithotomy with re-do ureterocystoneostomy was performed after failure of URS. Two patients with calculi discovered at removal of the ureteral stent were treated by URS. Conclusions: The incidence of urolithiasis in renal transplantation is uncommon. In the most of patients the condition occurs without pain. Metabolic anomalies and medical treatment after renal transplantation may cause stone formation. Advancements in endourology and interventional radiology have influenced the management of urolithiasis that can be actually treated with a minimal incidence of risk for the renal allograft.

LIVING-DONOR RENAL TRANSPLANTATION IN SEOPF

1990 ◽  
Vol 49 (1) ◽  
pp. 25-29 ◽  
Author(s):  
FRED SANFILIPPO ◽  
LEROY THACKER ◽  
WILLIAM K. VAUGHN
Keyword(s):  
Renal Transplantation ◽  
Living Donor

A Case of Living-Donor Renal Transplantation for Chronic Renal Failure Caused by Secondary Amyloidosis

2011 ◽  
Vol 43 (6) ◽  
pp. 2418-2420 ◽  
Author(s):  
K. Sakai ◽  
M. Okamoto ◽  
K. Koshino ◽  
T. Suzuki ◽  
S. Nobori ◽  
...  
Keyword(s):  
Renal Failure ◽  
Renal Transplantation ◽  
Chronic Renal Failure ◽  
Living Donor ◽  
Secondary Amyloidosis

scholarly journals Effect of cold ischaemia time on outcome after living donor renal transplantation

2016 ◽  
Vol 103 (9) ◽  
pp. 1230-1236 ◽  
Author(s):  
J. Nath ◽  
J. Hodson ◽  
S. W. Canbilen ◽  
J. Al Shakarchi ◽  
N. G. Inston ◽  
...  
Keyword(s):  
Renal Transplantation ◽  
Living Donor ◽  
Ischaemia Time ◽  
Cold Ischaemia Time

Renal transplantation in the first year of life: the treatment of choice for infants with end-stage renal disease.

1992 ◽  
Vol 2 (12) ◽  
pp. S228
Author(s):  
J S Najarian ◽  
P S Almond ◽  
M Mauer ◽  
B Chavers ◽  
T Nevins ◽  
...  
Keyword(s):  
Renal Failure ◽  
Renal Transplantation ◽  
Survival Rate ◽  
Living Donor ◽  
Patient Survival ◽  
First Year ◽  
End Stage Renal Failure ◽  
End Stage ◽  
First Year Of Life ◽  
Patient Survival Rate

The treatment of choice for end-stage renal failure within the first year of life is controversial. Between September 1970 and February 1991, we performed 28 kidney transplants (27 primary, 1 retransplant, 23 living donor, 5 cadaver) in infants less than 1 yr of age (mean, 7 +/- 2 months; range, 6 wk to 12 months). The 1-yr patient survival rate for living donor recipients was 100% versus 20% for cadaver recipients (P = 0.0001). The 1-yr graft survival rate for living donor recipients was 96% versus 20% for cadaver recipients (P = 0.001). The 1-yr patient survival rate for cyclosporin A (CSA) recipients (N = 12) was 100% versus 75% for non-CSA recipients (P = 0.03). The 1-yr graft survival rate for CSA recipients was 92% versus 75% for non-CSA recipients (P = 0.08). There was no difference in the number of rejection episodes or serum creatinine levels in CSA versus non-CSA recipients. Compared with pretransplant values, the mean posttransplant standard deviation scores (SDS) for height (N = 18), weight (N = 22), and head circumference (N = 8) improved: height SDS from -1.9 to -1.5 (not significant); weight SDS from -2.5 to 0.6 (P less than 0.0005); head circumference SDS from -2.0 to -0.7 (P = 0.01). Because no other renal replacement therapy can match these results, we conclude that renal transplantation is the treatment of choice for infants with end-stage renal failure.

Is recipient's body mass index a determinant of short term complications in early renal transplantation?

2020 ◽  
Vol 30 (12) ◽  
pp. 663-674
Author(s):  
V. Queruel ◽  
R. Kabore ◽  
A. Guillaume ◽  
K. Moreau ◽  
K. Leffondre ◽  
...  
Keyword(s):  
Body Mass Index ◽  
Renal Transplantation ◽  
Body Mass ◽  
Short Term
Sign in / Sign up

Export Citation Format

Share Document